Source-grounded facts extracted from SELLAS Life Sciences Group, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
SELLAS Life Sciences Group, Inc. shareholders approved Adjournment of the Annual Meeting to solicit additional proxies if necessary at the 2026-06-16 meeting.
“The Company’s stockholders approved an adjournment of the Annual Meeting, if necessary, to solicit additional proxies in favor of proposals 1, 2, 3 and 4.”
SELLAS Life Sciences Group, Inc. shareholders approved Non-binding advisory resolution on executive compensation at the 2026-06-16 meeting.
“The Company’s stockholders approved the non-binding, advisory resolution on the executive compensation of the Company’s named executive officers.”
SELLAS Life Sciences Group, Inc. shareholders approved Amendment to 2023 Amended and Restated Equity Incentive Plan to increase shares available by 20,000,000 at the 2026-06-16 meeting.
“The Company’s stockholders approved an amendment to the Company’s 2023 Amended and Restated Equity Incentive Plan (the “2023 Equity Plan”) to increase the number of shares of common stock available for sale under the 2023 Equity Plan by 20,000,000.”
SELLAS Life Sciences Group, Inc. shareholders approved Ratification of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-16 meeting.
“The Company’s stockholders ratified the appointment of Baker Tilly US, LLP (as the successor to Moss Adams LLP) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
SELLAS Life Sciences Group, Inc. shareholders approved Election of Class I Directors at the 2026-06-16 meeting.
“The Company’s stockholders re-elected each of the following nominees as a Class I director to the Board of the Company to hold office until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified.”
SELLAS Life Sciences Group, Inc. reported financial results for the full year ended December 31, 2025.
“SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2025 and providing a corporate update.”
SELLAS Life Sciences Group, Inc. issued up to 19,685,040 shares of Common Stock of warrant to a holder for in consideration of the Holder’s agreement to exercise the Existing Warrants.
“Pursuant to the Inducement Agreement, the Holder and the Company agreed that, subject to any applicable beneficial ownership limitations, the Holder would cash exercise 19,685,040 shares of Common Stock at an exercise price of $1.20 per share”
SELLAS Life Sciences Group, Inc. engaged Baker Tilly US, LLP as its auditor.
“On June 3, 2025, the Company engaged Baker Tilly as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Moss Adams LLP resigned as auditor of SELLAS Life Sciences Group, Inc..
“Moss Adams has resigned as the auditors of the Company and on June 3, 2025, the Audit Committee of the Company’s Board of Directors accepted the resignation of Moss Adams and approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm.”
SELLAS Life Sciences Group, Inc. reported the first quarter ended March 31, 2024 results: net income $9.6 million, EPS $0.21.
“SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update”
SELLAS Life Sciences Group, Inc. reported financial results for the year ended December 31, 2023.
“On March 28, 2024, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2023 and providing a corporate update.”
SELLAS Life Sciences Group, Inc. entered into Placement Agent Agreement with A.G.P./Alliance Global Partners (effective 2024-03-15).
“On March 15, 2024, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”) (the “Placement Agent”) pursuant to which the Company engaged A.G.P. as the exclusive placement agent in connection with the Offering.”
SELLAS Life Sciences Group, Inc. entered into Securities Purchase Agreement with institutional investors valued at approximately $20.0 million (effective 2024-03-15).
“On March 15, 2024, SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Registered Offering”), (i) an aggregate of 11,000,000 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (“Common Stock”) and (ii) an aggregate of 2,029,316 pre-funded warrants exercisable for shares of Common Stock (the “Pre-Funded Warrants”) to the Investors.”
Robert Francomano was terminated as Senior Vice President and Chief Commercial Officer at SELLAS Life Sciences Group, Inc..
“In addition, on March 6, 2024, Robert Francomano, Senior Vice President and Chief Commercial Officer of the Company, was terminated without cause, effective March 31, 2024.”
Barbara A. Wood was terminated as Executive Vice President, General Counsel and Corporate Secretary at SELLAS Life Sciences Group, Inc..
“On March 6, 2024, Barbara A. Wood, Executive Vice President, General Counsel and Corporate Secretary of SELLAS Life Sciences Group, Inc. (the “Company”), was terminated without cause, effective April 15, 2024.”
SELLAS Life Sciences Group, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 14, 2024, SELLAS Life Sciences Group, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notice has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on The Nasdaq Capital Market under the symbol “SLS” at this time. In accordance with Nas”
SELLAS Life Sciences Group, Inc. entered into Placement Agent Agreement with A.G.P./Alliance Global Partners (the "Placement Agent") (effective 2024-01-04).
“On January 4, 2024, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”) pursuant to which the Company engaged the Placement Agent as the exclusive placement agent in connection with the Offering.”
SELLAS Life Sciences Group, Inc. entered into Securities Purchase Agreements with certain investors (the "Purchasers") valued at approximately $9.0 million (effective 2024-01-04).
“On January 4, 2024, SELLAS Life Sciences Group, Inc., a Delaware corporation (the “Company”), entered into Securities Purchase Agreements (the “Purchase Agreements”) with certain investors (the “Purchasers).”
SELLAS Life Sciences Group, Inc. terminated Sales Agreement with Cantor Fitzgerald & Co. valued at up to an aggregate of $50,000,000 (effective 2024-01-02).
“On January 2, 2024, SELLAS Life Sciences Group, Inc. (the “Company”) and Cantor Fitzgerald & Co. (the “Agent”) mutually agreed to terminate the Controlled Equity Offering SM Sales Agreement, dated April 16, 2021 (“Sales Agreement”), pursuant to which the Company could from time to time offer and sell up to an aggregate of $50,000,000 of shares of its common stock”
SELLAS Life Sciences Group, Inc. amended Second Amendment to Sublease with Times Square Tower Associates LLC (effective 2023-12-11).
“SELLAS Life Sciences Group, Inc. (the “Company”) entered into a Second Amendment to Sublease (the “Sublease Amendment”), dated December 11, 2023, with Times Square Tower Associates LLC (the “Sublandlord”), which Sublease Amendment amends that certain Sublease, dated as of June 5, 2020 (the “Original Sublease”)”
SELLAS Life Sciences Group, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).
“December 6, 2023, SELLAS Life Sciences Group, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it no longer meets Nasdaq’s requirements for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) because, for a period of 30 consecutive business days, the market value of the Company’s common stock, calculated based upon the most recent total shares outstanding multiplied by the closing bid price per share, has not maintained a minimum of $35.0 million. The letter does not impact the Company’s”
SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended September 30, 2023.
“SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2023 and providing a corporate update.”
SELLAS Life Sciences Group, Inc. entered into Placement Agent Agreement with A.G.P./Alliance Global Partners and Maxim Group LLC (effective 2023-10-30).
“On October 30, 2023, the Company entered into a placement agency agreement (the "Placement Agent Agreement") with A.G.P./Alliance Global Partners ("A.G.P.") and Maxim Group LLC ("Maxim", and together with A.G.P., the "Placement Agents") pursuant to which the Company engaged A.G.P. and Maxim as the exclusive placement agents in connection with the Offering.”
SELLAS Life Sciences Group, Inc. entered into Purchase Agreement valued at approximately $4.0 million (effective 2023-10-30).
“On October 30, 2023, SELLAS Life Sciences Group, Inc., a Delaware corporation (the "Company"), entered into a Securities Purchase Agreement (the "Purchase Agreement") with a single institutional investor (the "Investor"), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investor (the "Offering"), (i) an aggregate of 3,100,000 shares (the "Shares") of common stock, par value $0.0001 per share, of the Company ("Common Stock") and (ii) an aggregate of 552,300 pre-funded warrants exercisable for shares of Common Stock (the "Pre-Funded Warrants") to the Investor, together with common warrants ("Common Warrants") to purchase up to 3,652,300 shares of Common Stock.”
SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended June 30, 2023.
“On August 10, 2023, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2023 and providing a corporate update.”
SELLAS Life Sciences Group, Inc. shareholders approved Non-binding advisory resolution on executive compensation at the 2023-06-20 meeting.
“The Company’s stockholders approved the non-binding, advisory resolution on the executive compensation of the Company’s named executive officers.”
SELLAS Life Sciences Group, Inc. shareholders rejected Amendment to Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation at the 2023-06-20 meeting.
“The affirmative vote of a majority of all outstanding common stock was required pursuant to Delaware law to approve the amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. Abstentions and broker non-votes were required to be treated as votes against this proposal. The amendment was not approved because an affirmative vote of all outstanding common stock was not received.”
SELLAS Life Sciences Group, Inc. shareholders approved Amendment to 2019 Equity Incentive Plan to increase authorized shares by 3,000,000 and delete expired evergreen provision at the 2023-06-20 meeting.
“The Company’s stockholders approved an amendment to the Company’s 2019 Equity Incentive Plan (the “2019 Equity Plan”) to increase the number of shares of Common Stock authorized for issuance under the 2019 Equity Plan by 3,000,000 shares and to delete the reference to the evergreen provision which expired on January 2, 2023 from the 2019 Equity Plan.”
SELLAS Life Sciences Group, Inc. shareholders approved Ratification of Moss Adams LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-20 meeting.
“The Company’s stockholders ratified the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
SELLAS Life Sciences Group, Inc. shareholders approved Election of Class I directors at the 2023-06-20 meeting.
“The Company’s stockholders re-elected each of the following nominees as a Class I director to the Board of the Company to hold office until the 2026 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified.”
SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended March 31, 2023.
“On May 11, 2023, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2023 and providing a corporate update.”
SELLAS Life Sciences Group, Inc. reported financial results for the year ended December 31, 2022.
“On March 16, 2023, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2022 and providing a corporate update.”
SELLAS Life Sciences Group, Inc. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at approximately $18.5 million (effective 2023-02-23).
“On February 23, 2023, SELLAS Life Sciences Group, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Cantor Fitzgerald & Co., as representative of the several underwriters named therein (collectively, the “ Underwriters ”), relating to an underwritten public offering of 7,220,217 shares (the “ Underwritten Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) and warrants (the “ Warrants ”, and together with the Underwritten Shares, the “ Securities ”) to purchase up to 7,220,217 shares of Common Stock.”
John T. Burns was appointed as Chief Financial Officer at SELLAS Life Sciences Group, Inc..
“On February 2, 2023, the Board of Directors (the “BOD”) of the Company appointed John T. Burns, the Company’s Senior Vice President, Finance and Chief Accounting Officer, as the Company’s Chief Financial Officer and principal financial officer.”
SELLAS Life Sciences Group, Inc. reported quarter ended September 30, 2022 results: net income Net loss was $7.0 million for the third quarter of 2022, or a basic and diluted loss per share of $0.34.
“On November 14, 2022, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2022 and providing a corporate update.”
Katherine Bach Kalin was elected as Director at SELLAS Life Sciences Group, Inc..
“On August 13, 2022, the Board of Directors (the “Board”) of SELLAS Life Sciences Group, Inc. (the “Company”) elected Katherine Bach Kalin as a member of the Board, effective immediately, to serve as a Class II director until the Company’s 2024 annual meeting of stockholders and thereafter until her successor is duly elected and qualified or until her earlier death, resignation or removal.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.